Lv41
640 积分 2024-04-26 加入
311eP Exploration of the mechanism of anlotinib in reversing PD-1 immunotherapy resistance: Insights from single-cell sequencing
7天前
已完结
Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
12天前
已完结
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
13天前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
13天前
已完结
Mid-term Combination Immunotherapy and its Effect on the Albumin–Bilirubin Score in Unresectable Hepatocellular Carcinoma
15天前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
18天前
已完结
The global burden of lung cancer: current status and future trends
18天前
已完结
Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy
1个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
1个月前
已完结
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer
1个月前
已完结
皖公网安备34019202002308
